Skip to main content
Clinical Trials/NCT05103098
NCT05103098
Unknown
Not Applicable

Sublingual Misoprostol 400 mcg and 800 mcg In Medical Treatment of First Trimester Missed Miscarriage: A Randomized Controlled Trial

hany farouk1 site in 1 country200 target enrollmentNovember 1, 2021

Overview

Phase
Not Applicable
Intervention
misoprostol 400 mcg
Conditions
Miscarriage
Sponsor
hany farouk
Enrollment
200
Locations
1
Primary Endpoint
Completeness of abortion
Last Updated
4 years ago

Overview

Brief Summary

The aim of this work is to compare the effectiveness of sublingual misoprostol 400 mcg versus 800 mcg for medical treatment of the first trimester missed miscarriage.

Detailed Description

the study will be made on female patients with the first trimester missed abortion confirmed by ultrasound. Participants will be divided into 2 groups one group (A) will receive sublingual Misoprostol 400 mcg and the other group(B) will receive sublingual Misoprostol 800 mcg every 4 hours in both groups up to 3 doses the aim of the study is to compare the efficacy of sublingual Misoprostol in complete termination of the first trimester missed abortion and which route is the best will less side effects.

Registry
clinicaltrials.gov
Start Date
November 1, 2021
End Date
March 31, 2023
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
hany farouk
Responsible Party
Sponsor Investigator
Principal Investigator

hany farouk

Clinical Professor

Aswan University Hospital

Eligibility Criteria

Inclusion Criteria

  • All women above 18 years of age
  • Less than 12 weeks of gestation.
  • Pregnancy is confirmed by pregnancy test or ultrasound scan.
  • missed abortion
  • Normal general and gynecological examination.

Exclusion Criteria

  • Hemodynamically unstable.
  • Suspected sepsis with temperature 38 °C.
  • Concurrent medical illness e.g. hematological, cardiovascular, thromboembolism,
  • respiratory illnesses, recent liver disease, or pruritus of pregnancy.
  • Presence of intrauterine contraceptive device (IUCD).
  • Suspect or proven ectopic pregnancy.
  • Failed medical or surgical evacuation before the presentation.
  • Known allergy to misoprostol.

Arms & Interventions

misoprostol 400 mcg

All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 400 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home. Two doses of misoprostol 800 mcg each (2 tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception

Intervention: misoprostol 400 mcg

misoprostol 800 mcg

All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home. Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception

Intervention: misoprostol 800 mcg

Outcomes

Primary Outcomes

Completeness of abortion

Time Frame: 7 days

Number of Participants with expulsion of Products of conception by visual inspection

Secondary Outcomes

  • Successful medical abortion(7 days)
  • amount of calculated blood loss following treatment(7 days)

Study Sites (1)

Loading locations...

Similar Trials